No abstract

A Precise, specific, linear, accurate and robust technique used to be developed for the simultaneous estimation of the, Emtricitabine, Tenofovir alafenamide and Doultegravir in pill dosage structure and Validated as per ICH Validation guidelines. Method was once optimised with the useful resource of Acquity BEH C18 125A° (100 × 2.1 mm, 1.7μ) column at a flow rate of 0.6ml/min, Mobile part was as soon as pH 3.8 Buffer, Methanol and Acetonitrile (50:40:10 respectively). The Column Oven temperature used to be maintained at 35°C and working wave dimension used to be selected at 274nm. The retention times of Emtricitabine, Tenofovir Alafenamide and Doultegravir have been determined to be 3.77, 6.34 and 7.67minutes respectively. The % RSD of the Emtricitabine, Tenofovir Alafenamide and Doultegravir had been and located to be 0.27%, 1.24% and 0.11% respectivelyIn Method precision Parameter, % Assay had been determined ninety five to 105.0% and p.c Recovery had been acquired as 98.9%, 100.4% and 100.0% for Emtricitabine, Tenofovir Alafenamide and Doultegravir respectively. Linearity was as soon as acquired as 0.999, 0.999 and 0.999 for Emtricitabine, Tenofovir Alafenamide and Doultegravir respectively. Analytical Range used to be determined from the linearity and accuracy for Emitricitabine used to be 50µg/mL to 150µg/mL, Tenofovir Alafenamide used to be as soon as 6.25µg/mL to 18.75µg/mL and Doultegravir was as soon as 12.5µg/mL to 37.5µg/mL.

Background: Amnesia is the loss of memory that majorly affects middle-aged to older people with a prevalence (1.0 -2.6%) of the overall population. Studies reported that scopolamine induction results in memory dysfunctions observed in demented patients. The current study evaluated the therapeutic potentials of armodafinil and its beneficial role in dementia, learning, and memory impairment. Armodafinil is the (-)-R enantiomer of modafinil. It is a nootropic used for the treatment of narcolepsy and the reversal of anesthetic effects. It binds to and thereafter inhibits the dopamine-reuptake pump, enhancing the concentration of dopamine in the synaptic gaps. Materials and Methods: 30 albino Wistar rats (250-300g) were included in the study, and they were randomly divided into five groups of six rats each (n = 6), two of which worked as controls: a control negative group and a control positive group. Scopolamine (3 mg/kg) was administered intraperitoneal to the control positive group on the 16 th day after receiving 200mg/ kg of Brahmi extract orally daily for 15 days. Armodafinil (15&30mg/kg) was given orally to the test groups for 15 days, and scopolamine (3mg/kg) was administered on the 16 th day. The behavioral measurements were performed at the end of the 16 th day, after which the animals were euthanized and brains were retrieved for biochemical assessments. Results: In the present study, armodafinil groups showed a significant increase in the % alterations in Y-maze, time spent in Morris water maze, motor activity on the spinning rod, and the response of steps climbed in the staircase test, and also substantial variation in levels of antioxidants and neurotransmitters in drug-treated groups were found. Both behavioral and biochemical analyses indicated the neuroprotective effects of armodafinil in memory dysfunction and are appreciated as a potential therapeutic approach for Parkinson's disease (PD). Conclusion: From the study armodafinil-treated groups showed retrieval of memory when compared to control negative (scopolamine-treated) group which showed heavy alteration in memory. The current study explored the neurobehavioral and memory-enhancing effects of armodafinil in scopolamine-induced amnesia which can be an essential tool to current clinical approaches toward neuroprotection.

Non-alcoholic fatty liver disease (NAFLD) is becoming a major public health problem due to the increasing incidence of obesity and diabetes in India for the last two decades. The present work is aimed to investigate the effect of aqueous extract of Colocasia esculenta against (AECE) high-fat diet-induced non-alcoholic fatty liver disease in Wistar albino rats. Wistar albino rats were assigned in to four groups as follows; Group I: Normal conventional diet, Group II: High fat diet, Group III & Group IV: Combined high fat diet and different doses of Colocasia esculenta (200 and 400 mg/kg, p.o) for 4 weeks.Treatment with aqueous extract of Colocasia esculenta(200mg/kg, 400mg/kg bw) significantly reduced the body weight and weight gain. In addition, it also significantly reduced the serum triglycerides, total cholesterol, LDL cholesterol, VLDL cholesterol and showed a significant increase in HDL cholesterol as well as significant improvement in liver cholesterol and triglyceride content. AECE treated rats exhibited a significant beneficial effects on levels of liver function markers and oxidative stress and also reversed the histopathological changes.The study suggested the therapeutic potential of AECE against NAFLD, acting in part through anti-obesity, antioxidant mechanisms, and liver marker enzymes.